Entrada Therapeutics
TRDA
48 hedge funds and large institutions have $243M invested in Entrada Therapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
4% more funds holding
Funds holding: 46 → 48 (+2)
1.52% more ownership
Funds ownership: 81.29% → 82.81% (+1.5%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
44% less capital invested
Capital invested by funds: $434M → $243M (-$191M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.34M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.08M |
| 3 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
+$1.86M |
| 4 |
State Street
Boston,
Massachusetts
|
+$751K |
| 5 |
Walleye Capital
New York
|
+$479K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.12M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.37M |
| 3 |
Millennium Management
New York
|
-$796K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$476K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$190K |
TRDA Hedge Fund Activity: Q1 2022 in Review
48 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2022, worth a combined $243M — down 44% from $434M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TRDA positions and 6 closed out — a net gain of 2 holders — while 14 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $6.34M. The largest seller was Wellington Management Group, cutting an estimated $6.12M.
- 48 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2022, up from 46 in Q4 2021.
- Funds reported $243M of Entrada Therapeutics stock for Q1 2022, down 44% quarter-over-quarter.
- 8 funds opened new Entrada Therapeutics positions in Q1 2022 and 6 closed out, a net change of +2 holders.
- The largest Entrada Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $6.34M added.
- The largest Entrada Therapeutics seller in Q1 2022 was Wellington Management Group, an estimated $6.12M sold.
Based on aggregated 13F filings for Q1 2022.